Journal: Journal of Translational Medicine
Article Title: Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification
doi: 10.1186/s12967-025-06682-1
Figure Lengend Snippet: Malignancy phenotypes and experimental validation of hubgenes. ( A ) Kaplan-Meier of OS with log-rank test in TCGA BLCA cohort, respectively, for the grouping of the median expression of DAD1, CYP1B1, and REXO2. ( B ) The relative expression of different stages for DAD1, CYP1B1, and REXO2, respectively. ( C ) The relative expression of different grades for DAD1, CYP1B1, and REXO2, respectively. Ns represents P-value > 0.05; *, **, ***, **** represents P-value < 0.05. ( D ) Western blotting of DAD1, CYP1B1, and REXO2 proteins in different tumor stages. β-actin was used as the reference protein. ( E ) The bar graphs show the relative expression of DAD1, CYP1B1, and REXO2 proteins in different tumor stages. ( F ) Immunohistochemistry of DAD1 and CYP1B1 proteins in four tumor stages
Article Snippet: The slides were blocked for one hour and then incubated overnight at 4 °C with primary antibodies against DAD1 (1:100; CSB-PA03124A0Rb, CUSABIO, https://www.cusabio.com/ , China) and CYP1B1 (1:100; R24037 , Zenbio, China).
Techniques: Biomarker Discovery, Expressing, Western Blot, Immunohistochemistry